Hexa Reports Market Research Reports and Insightful Company Profiles 2016 Ophthalmology Pipeline Review: Analysis of Companies Involved in Therapeutics Development Ophthalmology Drug Development Pipeline Review, 2016 report provides comprehensive information on the pipeline development landscape for glaucoma, age-related macular degeneration, diabetic retinopathy, diabetic macular edema and keratoconjunctivitis sicca (dry eye), from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field. Browse Detail Ophthalmology Drug Development Pipeline Review Market Research Report @ http://www.hexareports.com/report/ophthalmology-drug-development-pipeline-review2016/details Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious longterm co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmology, there are currently no curative therapies for any of these indications. In particular, there are strong unmet needs within age-related macular degeneration and glaucoma, which can lead to blindness if not adequately treated. Hexa Reports Market Research Reports and Insightful Company Profiles Although there is a high degree of failure and uncertainty within the R&D of pharmaceuticals, there is a great deal of interest in ophthalmology development. Overall, there are over 700 products in active development in the ophthalmology therapy area, making it one of the largest therapy area pipelines. Although two thirds of products in development for ophthalmology disorders are at the Discovery or Preclinical stage of development, the number of drugs in the pipeline is very high, creating strong potential for a blockbuster drug to enter the market. Get Sample PDF of Report @ http://www.hexareports.com/sample/169580 2016 Ophthalmology Drug Development Pipeline Review Helps to Answer Following Questions:  Which companies are the most active within the pipeline for ophthalmology?  Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?  To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?  What are the most important R&D milestones and data publications to have occurred in ophthalmology? Reasons To Buy 1. Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication. 2. Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each. 3. Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these. 4. Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration. Detail TOC of Ophthalmology Drug Development Pipeline Review:  Introduction  Therapeutics Development by Stage  Therapeutics under Development by Companies  Therapeutics under Investigation by Universities/Institutes  Pipeline Products Glance  Products under Development by Companies  Products under Investigation by Universities/Institutes  Companies Involved in Therapeutics Development  Therapeutics Assessment  Dormant Projects  Discontinued Products Hexa Reports Market Research Reports and Insightful Company Profiles   Product Development Milestones Appendix Explore Latest Market Research Reports: Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies: http://www.hexareports.com/report/gastric-cancer-therapeuticsin-asia-pacific-markets-to-2022 Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies: http://www.hexareports.com/report/osteoporosis-therapeutics-in-asia-pacific-markets-to-2022 About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, Phone Number 1-800-489-3075 Email Us: [email protected] Our Website: http://www.hexareports.com/ Visit our Blog: http://hexareports.blogspot.com/ Like our Facebook page: https://www.facebook.com/hexareportsindustry/ Follow us on LinkedIn: https://www.linkedin.com/company/hexa-reports-inc-

Analysis of innovation in the ophthalmology markets in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape surrounding first-in-class products in ophthalmology, and highlights opportunities for in-licensing.